Pharmacist Dr. Antje Behring increases health care at Pharma Germany

Pharmacist Dr. Antje Behring increases health care at Pharma Germany

A profit for health care: Antje Behring strengthens Pharma Germany

Pharma Germany has a new member of the healthcare department from September 1st: Pharmacist Dr. Antje Behring. Behring had previously worked for the Federal Joint Committee (G-BA) since 2011, first as a speaker and since 2020 as department head in the field of medicines. Through her work in the G-BA, she has extensive knowledge of the prescription of medicinal products within the framework of statutory health insurance. She is particularly experienced in the early benefit assessment of pharmaceuticals and in questions of evidence generation for the evaluation of medicinal products, even at European level. It represented the G-BA on these topics in national and international events.

Pharma Germany is enthusiastic about working with Ms. Behring, as Dorothee Brakmann, the general manager of the association. With Antje Behring, Pharma Germany can further expand his expertise in the regulatory, pharmaceutical and health -political aspects of the supply of drugs. Ms. Behring knows the German health system almost only a few other people and will also personally be a valuable addition to the team.

Ensure sustainable and innovative health care

Pharma Germany e.V. is the pharmaceutical association with the highest membership in Germany and is committed to the interests of the German pharmaceutical industry. The association promotes the dialogue between politics, business and society to ensure sustainable and innovative health care. With around 400 member companies, Pharma Germany represents the interests of an important industry.

The strengthening of the health care department by Antje Behring is a big step in this direction. With her expertise and experience, she will help Pharma Germany to react even better to the challenges in the field of pharmaceutical supply. This is of great importance for patients and health care as a whole.

The admission of Antje Behring to the Pharma Germany team is considered a positive signal for the industry, as this shows that renowned specialists from the public sector are willing to participate in the association's work. This underlines the relevance and influence of the association in politics and the health industry.

Overall, cooperation with Antje Behring is an important step for Pharma Germany in order to reconcile the needs of the pharmaceutical industry and the requirements of health care. The goal remains a sustainable and innovative health care for all patients in Germany.